Compare AbCellera Biologics Inc (ABCL) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Extra Space Storage, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Extra Space Storage, Inc. trades at $144.92 (market cap $31.21B). The key difference: Extra Space Storage, Inc. is far larger — about 13.3× AbCellera Biologics Inc's market cap, and Extra Space Storage, Inc. pays a 4.39% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EXR | |
|---|---|---|
Market Cap | $2.35B | $31.21B |
Sector | Health | Real Estate |
52-Week High | $8.12 | $152.75 |
52-Week Low | $2.78 | $126.67 |
Enterprise Value | $1.99B | $45.01B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
EXR trades at $147.73, down 1.04% on the day, with a neutral technical signal and strong fundamentals including a 27.66% net income margin and consistent earnings beats. The company maintains robust cash flow from operations at $1.85B in 2025 and recently priced $550 million in senior notes. Analyst consensus is mixed with a $152.86 price target, while technical support sits at $144.
Outlook remains stable with revenue growth and dividend reliability, but risks include high leverage with a 46.63% debt-to-asset ratio and competitive pressures. The stock offers value near consensus targets, though margin compression and interest rate sensitivity warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
